WO2002092001A3 - Compositions and methods for the therapy and diagnosis of lung cancer - Google Patents

Compositions and methods for the therapy and diagnosis of lung cancer Download PDF

Info

Publication number
WO2002092001A3
WO2002092001A3 PCT/US2002/014975 US0214975W WO02092001A3 WO 2002092001 A3 WO2002092001 A3 WO 2002092001A3 US 0214975 W US0214975 W US 0214975W WO 02092001 A3 WO02092001 A3 WO 02092001A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
lung cancer
therapy
polypeptides
Prior art date
Application number
PCT/US2002/014975
Other languages
French (fr)
Other versions
WO2002092001A2 (en
Inventor
Michael J Lodes
Tongtong Wang
Liqun Fan
Paul A Algate
Patricia D Mcneill
Heather Secrist
Darin R Benson
Robert A Henderson
Raodoh Mohamath
Original Assignee
Corixa Corp
Michael J Lodes
Tongtong Wang
Liqun Fan
Paul A Algate
Patricia D Mcneill
Heather Secrist
Darin R Benson
Robert A Henderson
Raodoh Mohamath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/854,133 external-priority patent/US6759508B2/en
Application filed by Corixa Corp, Michael J Lodes, Tongtong Wang, Liqun Fan, Paul A Algate, Patricia D Mcneill, Heather Secrist, Darin R Benson, Robert A Henderson, Raodoh Mohamath filed Critical Corixa Corp
Priority to EP02739247A priority Critical patent/EP1516049A4/en
Priority to AU2002311909A priority patent/AU2002311909A1/en
Publication of WO2002092001A2 publication Critical patent/WO2002092001A2/en
Publication of WO2002092001A3 publication Critical patent/WO2002092001A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
PCT/US2002/014975 2001-05-11 2002-05-10 Compositions and methods for the therapy and diagnosis of lung cancer WO2002092001A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02739247A EP1516049A4 (en) 2001-05-11 2002-05-10 Compositions and methods for the therapy and diagnosis of lung cancer
AU2002311909A AU2002311909A1 (en) 2001-05-11 2002-05-10 Compositions and methods for the therapy and diagnosis of lung cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/854,133 US6759508B2 (en) 2000-09-01 2001-05-11 Compositions and methods for the therapy and diagnosis of lung cancer
US09/854,133 2001-05-11

Publications (2)

Publication Number Publication Date
WO2002092001A2 WO2002092001A2 (en) 2002-11-21
WO2002092001A3 true WO2002092001A3 (en) 2005-01-13

Family

ID=25317820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/014975 WO2002092001A2 (en) 2001-05-11 2002-05-10 Compositions and methods for the therapy and diagnosis of lung cancer

Country Status (3)

Country Link
EP (1) EP1516049A4 (en)
AU (1) AU2002311909A1 (en)
WO (1) WO2002092001A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7226791B2 (en) * 2003-06-02 2007-06-05 Bristol-Myers Squibb Company Polynucleotides encoding novel guanylate binding proteins (GBP's)
JP5644110B2 (en) * 2008-08-05 2014-12-24 東レ株式会社 Cancer detection method
BRPI0911926A2 (en) 2008-08-05 2020-08-18 Toray Industries, Inc pharmaceutical compositions, antibodies and uses of an antibody or a fragment thereof.
KR101871704B1 (en) 2010-02-04 2018-06-27 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
CN102822335B (en) 2010-02-04 2015-09-30 东丽株式会社 Cancer treat and/or prevent pharmaceutical composition
JP5923984B2 (en) 2010-02-04 2016-05-25 東レ株式会社 Pharmaceuticals for the treatment and / or prevention of cancer
EP2532680B1 (en) 2010-02-04 2015-04-29 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JP5742713B2 (en) 2010-02-04 2015-07-01 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer
KR102041832B1 (en) 2011-08-04 2019-11-08 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
WO2013018885A1 (en) 2011-08-04 2013-02-07 東レ株式会社 Method for detecting pancreatic cancer
PT2740793T (en) 2011-08-04 2018-02-23 Toray Industries Drug composition for cancer treatment and/or prevention
WO2013018883A1 (en) 2011-08-04 2013-02-07 東レ株式会社 Cancer treatment and/or prevention drug composition
TR201808595T4 (en) 2011-08-04 2018-07-23 Toray Industries Pharmaceutical composition for the treatment and / or prophylaxis of cancer diseases.
MX351682B (en) 2011-08-04 2017-10-25 Toray Industries Pharmaceutical composition for treatment and/or prophylaxis of cancer.
RU2611197C2 (en) 2011-08-04 2017-02-21 Торэй Индастриз, Инк. Pharmaceutical composition for cancer treatment and/or prevention
IN2014KN01715A (en) 2012-02-21 2015-10-23 Toray Industries
EP2818481B1 (en) 2012-02-21 2019-08-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PL2818482T3 (en) 2012-02-21 2019-11-29 Toray Industries Pharmaceutical composition for treatment of cancer
EP2824114B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
CN104220095B (en) 2012-03-30 2016-09-07 东丽株式会社 The treatment of liver cancer and/or prophylactic compositions
CN104203281B (en) 2012-03-30 2019-07-26 东丽株式会社 The treatment of gallbladder cancer and/or prophylactic compositions
RU2646464C2 (en) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Method for cancer detection
KR102056654B1 (en) 2012-07-19 2019-12-17 도레이 카부시키가이샤 Cancer detection method
TR201819812T4 (en) 2013-08-09 2019-01-21 Toray Industries Pharmaceutical Composition for Cancer Treatment and / or Prevention Purpose

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20014718A3 (en) * 1999-06-30 2003-01-15 Corixa Corporation Compounds and methods for therapy and diagnostic of lung cancer
PL366626A1 (en) * 2000-03-29 2005-02-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress

Also Published As

Publication number Publication date
AU2002311909A1 (en) 2002-11-25
WO2002092001A2 (en) 2002-11-21
EP1516049A2 (en) 2005-03-23
EP1516049A4 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002016413A3 (en) Cripto tumour polypeptide
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002012328A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2002058534A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003086175A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002739247

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002739247

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)